Kanilad

Lacosamide, the active ingredient in Kanilad, is an anticonvulsant presented as an oral tablet for oral use. It is used as adjunctive therapy for partial‑onset seizures in epilepsy.

GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug indicated for focal seizure disorders.

Partial‑onset seizures: adjunctive therapy to reduce seizure frequency in patients with epilepsy. Focal epilepsy: improves seizure control when added to existing antiepileptic regimens.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Cardiac conduction abnormalities: PR‑interval prolongation that may lead to arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, swelling, or anaphylaxis. - Hepatic enzyme elevation: significant increase in liver function tests. - Respiratory depression: marked reduction in breathing effort.

Before initiating therapy, consider the following safety measures.

Renal impairment: assess kidney function and monitor for accumulation. Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. Pregnancy: risk unknown; use only if potential benefit justifies the risk. Concomitant antiepileptic drugs: observe for changes in seizure control. Avoid abrupt discontinuation: taper gradually to prevent seizure exacerbation. Store at room temperature: keep in the original packaging, protect from moisture and heat.

Lacosamide can interact with several medications; awareness of the interaction level is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma concentrations. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): risk of additive cardiac conduction delay. - Other sodium‑channel blockers (e.g., carbamazepine): heightened risk of central nervous system depression.

Moderate Interactions (Monitor Closely): - Additional antiepileptic drugs: may alter overall seizure control efficacy. - Alcohol: can intensify dizziness and sedation. - CYP2C19 substrates: potential alteration of their plasma levels.